Qingdao Haier Biomedical Co.,Ltd (SHA:688139)
China · Delayed Price · Currency is CNY 35.85
+0.66 (1.88%)
At close: Sep 30, 2026
SHA:688139 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,215 | 9,924 | 11,112 | 12,824 | 20,078 | 28,796 | |
Market Cap Growth | 10.43% | -10.69% | -13.35% | -36.13% | -30.28% | 39.10% |
Enterprise Value | 9,939 | 8,845 | 9,530 | 10,935 | 17,327 | 25,931 |
Last Close Price | 35.85 | 31.39 | 34.25 | 38.91 | 60.29 | 85.92 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 43.74 | 39.58 | 30.31 | 31.58 | 33.42 | 34.08 |
Forward PE | 39.40 | 19.67 | 17.53 | 18.53 | 25.87 | 39.80 |
PS Ratio | 4.62 | 4.26 | 4.87 | 5.62 | 7.01 | 13.55 |
PB Ratio | 2.40 | 2.15 | 2.41 | 2.89 | 4.84 | 7.91 |
P/TBV Ratio | 3.37 | 3.05 | 3.46 | 3.98 | 6.17 | 9.42 |
P/FCF Ratio | 38.69 | 66.77 | 67.36 | 177.91 | 59.37 | 74.39 |
P/OCF Ratio | 29.79 | 37.04 | 38.10 | 51.45 | 31.75 | 48.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.09 | 3.80 | 4.17 | 4.79 | 6.05 | 12.20 |
EV/EBITDA Ratio | 30.83 | 29.12 | 22.55 | 26.63 | 27.65 | 52.80 |
EV/EBIT Ratio | 46.57 | 45.18 | 31.08 | 34.94 | 30.69 | 58.67 |
EV/FCF Ratio | 34.29 | 59.51 | 57.77 | 151.70 | 51.24 | 66.99 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.08 | 0.10 | 0.05 | 0.04 | 0.04 | 0.01 |
Debt / FCF Ratio | 0.09 | 0.20 | 0.14 | 0.25 | 0.08 | 0.02 |
Net Debt / Equity Ratio | -0.33 | -0.27 | -0.38 | -0.43 | -0.71 | -0.80 |
Net Debt / EBITDA Ratio | -4.81 | -4.15 | -4.15 | -4.63 | -4.71 | -5.90 |
Net Debt / FCF Ratio | -5.26 | -8.49 | -10.64 | -26.39 | -8.72 | -7.49 |
Asset Turnover | 0.43 | 0.40 | 0.40 | 0.41 | 0.55 | 0.48 |
Inventory Turnover | 4.05 | 3.67 | 4.09 | 4.53 | 4.84 | 3.58 |
Quick Ratio | 1.95 | 1.61 | 2.09 | 2.27 | 2.68 | 2.69 |
Current Ratio | 2.66 | 2.45 | 2.59 | 2.69 | 2.95 | 3.02 |
Return on Equity (ROE) | 5.57% | 5.52% | 8.41% | 9.60% | 15.72% | 26.44% |
Return on Assets (ROA) | 2.33% | 2.11% | 3.39% | 3.55% | 6.79% | 6.25% |
Return on Invested Capital (ROIC) | 6.48% | 6.06% | 10.76% | 15.88% | 52.76% | 60.40% |
Return on Capital Employed (ROCE) | 4.50% | 4.20% | 6.40% | 6.80% | 13.10% | 11.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.28% | 2.53% | 3.30% | 3.17% | 2.99% | 2.94% |
FCF Yield | 2.58% | 1.50% | 1.49% | 0.56% | 1.68% | 1.34% |
Dividend Yield | 0.92% | 1.05% | 1.37% | 1.32% | 0.75% | 0.58% |
Payout Ratio | 40.40% | 58.77% | 44.48% | 35.16% | 27.04% | 14.30% |
Buyback Yield / Dilution | 1.48% | 0.84% | 0.37% | 0.20% | -0.06% | 2.43% |
Total Shareholder Return | 2.40% | 1.89% | 1.75% | 1.52% | 0.68% | 3.01% |